ARCTURUS THERAPEUTICS HOLDINGS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.48 USD | -6.81% |
|
-7.94% | -22.36% |
Presenter SpeechJoseph Payne (Executives)Good morning, and welcome to the 2024 Annual Meeting ...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
26.27
USD
Average target price
74.75
USD
Spread / Average Target
+184.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.36% | 707M | |
| +23.13% | 52.73B | |
| +37.49% | 39B | |
| -8.73% | 38.52B | |
| +28.09% | 30.38B | |
| -12.26% | 26.39B | |
| +10.57% | 26.08B | |
| +45.05% | 14.15B | |
| +32.23% | 12.6B | |
| -6.56% | 11.51B |
- Stock Market
- Equities
- ARCT Stock
- News Arcturus Therapeutics Holdings Inc.
- Transcript : Arcturus Therapeutics Holdings Inc. - Shareholder/Analyst Call
